【Seoul, THURSDAY, July 9】 Greenstatin, Green Cross′s anti-angiogenic drug has obtained Investigational New Drug (IND) application from the US FDA.
It is the first time that a new anticancer biodrug developed by purely Korean technology received the approval of its IND application from the US FDA.
Green Cross has been developing Greenstatin with Mogam Biotechnology Research Institute and MD Anderson Caner Center since 2006.
Greenstatin is Known to be very effective against brain cancel, lung cancer and prostate cancer.
And its patents for materials have already been registered in many countries(the US and Europe etc.)
Green Cross plans to roll out Greenstatin in the market in 2014, expecting to produce and supply it at a low price thanks to its well-established mass production technology for recombinant proteins.
Greenstatin was selected as an international cooperative research project for the New Drug Development program, supported by the Ministry of Health and Welfare(MOHWF).
And a total of 10.8 billion won was scheduled to be provided to the research project by MOHWF during 6 years from 2005 to 2011(5.4 billion won from the government and 5.4 billion won from a consortium of companies).<헬스코리아뉴스>
▲ FDA, 녹십자 바이오신약 ‘그린스타틴’ 임상시험 승인
